Xcel Brands Taps This Award-Winning CFDA Designer For New Collection

Xcel Brands Inc (NASDAQ:XELB) is planning to launch a new collection C. Wonder by Christian Siriano. The company has also appointed…
  • Xcel Brands Inc (NASDAQ:XELB) is planning to launch a new collection C. Wonder by Christian Siriano.
  • The company has also appointed Christian Siriano as the Creative Director of the new brand, which will launch in the spring of 2023.
  • Fashion designer Siriano has helmed his own brand since 2008 and has been a member of the Council of Fashion Designers of America (CFDA) since 2013.
  • His designs have been worn on the red carpet by numerous celebrities, including current FLOTUS Jill Biden, former FLOTUS Michelle Obama, Angelina Jolie, Oprah, Zendaya, Ariana Grande, Julianne Moore, Lady Gaga, Tiffany Haddish, Billy Porter, Cardi B, Amy Adams, Scarlett Johansson, Whoopi Goldberg and Julia Roberts, and more.
  • Siriano will continue to design his own collection while bringing his signature influence to the new modern ready-to-wear and accessories collections.
  • He will also serve as the public face and voice of the brand, including appearing on HSN’s broadcast and streaming service in 2023.
  • In addition to C. Wonder by Christian Siriano, Xcel Brands produces and distributes sportswear and dresses under the Halston and H Halston labels.
  • Price Action: XELB shares are trading lower by 3.69% at $1.07 on the last check Friday.
  • Photo Via Wikimedia Commons
Total
0
Shares
Related Posts
Read More

Ipsen Announced Onivyde Regimen Demonstrated Statistically Significant Improvement in Overall Survival in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma; Trial Met its Primary Endpoint and Key Secondary Endpoint

Ipsen (Euronext: IPN; ADR: IPSEY) announced the Phase III NAPOLI 3 trial of Onivyde® (irinotecan liposome injection) plus 5 fluorouracil/leucovorin and oxaliplatin (NALIRIFOX regimen) met its primary endpoint demonstrating clinically meaningful and statistically significant improvement in overall survival compared to nab-paclitaxel plus gemcitabine in 770 previously untreated patients with metasta

IPSEY